Biotechnology Stocks in Bearish Claws: (NASDAQ:NPSP), (NASDAQ:BIIB), (NASDAQ:ARNA), (NASDAQ:DNDN).
Houston, TX – January 4, 2013 — (Net PR News) – AnotherWinningTrade.com offers its daily alerts and market content newsletter to investors looking for the best information available! AnotherWinningTrade.com provides its subscribers with useful, timely information and exclusive alerts on penny stocks, mid cap stocks and large cap stocks with the potential to deliver gains of 100%-200% or more. We have the top alerts in the industry. To receive our FREE, comprehensive newsletter, visit AnotherWinningTrade.com.
Today’s Stocks in focus are: NPSP, BIIB, ARNA, DNDN
NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) moved down -4.70% to close at the end of the trading day at $8.72.
NPSP showed negative weekly, monthly and quarterly performance of -1.91%, -14.00% and -5.11%, respectively. The shares floated remained 86.35 million.
NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) has intended to present at the 31st Annual J.P. Morgan Healthcare Conference. The conference will be held on Wednesday, January 9, 2013 at 9:00 a.m. PT. in San Francisco. The Company’s investors as well as other interested parties will be able to access the webcast via the NPS Pharmaceuticals’ website, at the investor’s event page.
Get A Free Report And Detailed Analysis On NPSP CLICK HERE To Read
Biogen Idec Inc. (NASDAQ:BIIB) decreased -1.43% and closed at the end of the previous session at $147.86. The market capitalization of BIIB remained 34.98 billion.
On January 3, 2013, BIIB traded with hot volume of 5.82 million shares and its average trading capacity was 935,580 shares.
The weekly, monthly and quarterly performances of the stock remained in the red -0.38%, -1.79% and -1.39%, respectively.
Biogen Idec Inc. (NASDAQ:BIIB) has planned to take part at the event of the 31st Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2013 at 2:30 p.m. PT, 5:30 p.m. Eastern Time.
How Should Investors React To BIIB Now? Find Out In This TREND ANALYSIS REPORT
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) was among the negative movers of the Biotechnology industry and fell -0.78%. The volume of the stock remained 5.52 million shares and average volume was 7.02 million shares.
ARNA’s weekly and monthly performances were positive +2.17% and +3.11%, respectively. The beta of ARNA was 0.24.
How Should Investors Trade ARNA Now? Don’t Trade ARNA Until You Read This TREND ANALYSIS REPORT
Dendreon Corporation (NASDAQ:DNDN) was also among the stocks of the Biotechnology industry which were in bearish claws and fell -0.52%. The volume of the stock remained 4.20 million shares and average volume was 4.22 million shares.
The market capitalization of DNDN remained 893.50 million.
The 3 months performance of the stock was outstanding and showed a gain of +28.67%. The year to date performance also cleared it as a bull as it grew+9.45%.
Is DNDN A Solid Investment At These Levels? Find Out Exactly Where DNDN Is Headed With This TREND ANALYSIS REPORT
Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid IO News Wire twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation; do no trading of any kind and send no faxes or emails.